The AMCP (Academy of Managed Care Pharmacy) Format 5.0 for Formulary Submissions is the industry standard for presenting evidence to U.S. healthcare decision-makers to support formulary reviews. Manufacturers are not permitted to proactively provide AMCP dossiers to formulary decision makers,…
Driving Launch Excellence Everyone in the life sciences industry knows that simply building an innovative product is not enough to ensure business success. Launching new products and penetrating the market are key, and commercial learning and development (commercial L&D), responsible…
Defining the Timing, Rigor, and Impact of Commercial Insights from Preclinical through Post-Launch R&D and clinical functions take precedence in early planning, often delaying commercial involvement. This leads to missed opportunities to influence target product profile (TPP) design, trial endpoints,…
GSK, Amgen and AstraZeneca Lead the Pack in the 2025 Digital Marketing Competency Report Trinity is pleased to announce the release of its 5th Annual TGaS Digital Marketing Competency Report, a comprehensive analysis benchmarking digital maturity and omnichannel innovation across…
How will Joint Clinical Assessment impact patient access to medicines in Europe? Joint clinical assessment (JCA) has been implemented for new cancer medicines and advanced therapy medicinal products (ATMP) from January 2025 in the European Union (EU). The first panel…
Traits of a High Performing Learning Organization Through the 2020s, life sciences leaders have dealt with one challenge after another. The shock of the COVID-19 pandemic. Sticky inflation. Return-to-office mandates. The intense pressure to perform in the face of disruptive…
How are Commercial, Medical and Market Access organizations evolving to develop capabilities and accelerate innovation in 2025 and beyond? Executive leaders are focused on making informed organizational decisions to propel the evolution of capabilities in this rapidly changing global economy. As you strategize to optimize structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ 2025 Spring Summit.
The healthcare industry has long been known for its significant environmental impact, including contributing ~5% of total global emissions. As awareness of this impact has increased, life sciences companies are now actively committing to climate resilience and environmental sustainability through…
Joint clinical assessment (JCA) is a European Union (EU) initiative intended to improve patient access to health technologies in Europe through a harmonized clinical health technology assessment (HTA) process. From January 2025, all new oncology medicines and advanced therapy medicinal…
The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research organization dedicated to assessing the value of healthcare interventions, including diagnostics, devices, digital therapeutics and prescription drugs. Although ICER’s assessments do not represent a mandate for product…